DUSA Pharmaceuticals to Present at the Jefferies Healthcare Conference on June 28
For release at 8:00 a.m.
DUSA PHARMACEUTICALS TO PRESENT AT THE
JEFFERIES HEALTHCARE CONFERENCE ON JUNE 28
Wilmington, MA. June 25, 2007 - DUSA Pharmaceuticals, Inc. (NASDAQ GM: DUSA) announced today that Robert F. Doman, President and Chief Executive Officer, will be presenting at the Jefferies Healthcare Conference on Thursday, June 28, 2007 at 11:20 a.m. Eastern Daylight Time in New York, NY.
Live Audio Webcast
The presentation will be available as a live audio webcast on the Company's website at www.dusapharma.com and a copy of the slide presentation together with the audio will be archived on the Company's website following the presentation.
About DUSA
DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan® Photodynamic Therapy (PDT) technology platform, and complementary dermatology products. Levulan PDT is currently indicated for the treatment of minimally to moderately thick actinic keratoses (Grade 1 or 2) of the face or scalp, and is being studied for the treatment of acne. DUSA's other dermatology products include ClindaReachTM, Nicomide® and the AVAR® line. DUSA is also sponsoring research for additional indications for internal uses of Levulan PDT. DUSA is based in Wilmington, MA. Please visit the company's website at www.dusapharma.com for more information.
For further information contact:
Shari Lovell, Director, Shareholder Services
Tel: 416.363.5059 Fax 416.363.6602
lovells@dusapharma.com